Detrimental roles of TNF-alpha in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-alpha

Journal of Thrombosis and Thrombolysis

Volumn 44, Issue 4, 2017, Pages 565-570

  Bećarević, Mirjana ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Biopharmaceuticals against TNF alpha; TNF alpha

Indexed keywords

PHOSPHOLIPID ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIBODY PRODUCTION; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL STUDY; DRUG EFFECT; EXPERIMENTAL ANTIPHOSPHOLIPID SYNDROME; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SECONDARY ANTIPHOSPHOLIPID SYNDROME; SIDE EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85031396590     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-017-1571-4     Document Type: Review

References (48)

1. Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 4:295–306
2. D’Ippolito S, Meroni PL, Koike T, Veglia M, Scambia G, Di Simone N (2014) Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder. Autoimmun Rev 13:901–908
3. Bertolaccini ML, Ammengual O, Andreolii L et al (2014) 14th International congress on antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13:917–930
4. van den Hoogen LL, van Roon JAG, Radstake TRDJ et al (2006) Delineating the deranged immune system in the antiphospholipid syndrome. Autoimmun Rev. doi:10.1016/j.autrev.2015.08.011
5. Salmon JE, Girardi G (2008) Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol 77:51–56
6. Meroni PE, Raschi E, Testoni C, Borghi MO (2004) Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 112:169–174
7. Noack M, Miossec P (2017) Selected cytokine pathways in theumatoid arthritis. Semin Immunopathol. doi: 10.1007/s00281-017-0619-z
8. Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Llurba E, Gris JM (2017) Tumor necrosis factor alpha and pregnancy: focus on biologics. An update and comprehensive review. Clin Rev Allerg Immunol. doi:10.1007/s12016-016-8596-x
9. Sedger LM, McDermott MF (2014) TNF and TNF receptors: from mediators of cell death and inflammation to therapeutic giants-past, present and future. Cytokine Growth Factor Rev. doi:10.1016/j.cytogfr.2014.07.016
10. Aringer M, Smolen JS (2012) Therapeutic blockade of TNF in patients with SLE—Promising or crazy? Autoimmun Rev 11:321–325
11. Abbas AK, Lichtmann AH, Pober JS (2015) Cellular and molecular immunology. WB Saunders Company, Philadelphia
12. Berman J, Girardi G, Salmon JE (2005) TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 174:485–490
13. Atzeni F, Talotta R, Salaffi F et al (2013) Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 12:703–708
14. Sinagra E, Perricone G, Romano C, Cottone M (2013) Heart failure and anti-tumor necrosis factor alpha in systemic chronic inflammatory diseases. Eur J Int Med 24:385–392
15. Brzustewicz E, Bryl E (2015) The role of cytokines in the pathogenesis of rheumatoid arthritis-practical and potential application of cytokines as biomarkers and targets of personalized therapy. Cytokine 76:527–536
16. http://www.janssenlabels.com/package-insert/product-patient-information/SIMPONI-medicationguide.pdf, http://www.remicadehcp.com/shared/product/remicade/medication-guide.pdf
17. http://www.rxabbvie.com/pdf/humira_medguide.pdf
18. http://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/enbrel/enbrel_mg.pdf
19. https://www.cimzia.com/sites/default/files/docs/Prescribing_Information.pdf
20. Benhamou Y, Miranda S, Armengol G et al (2015) Infliximab improves endothelial dysfunction in a mouse model of antiphospholipid syndrome: role of reduced oxidative stress. Vascul Pharmacol 71:93–101
21. Prinz N, Clemens N, Canisius A, Lackner KJ (2013) Endosomal NADPH-oxidase is critical for induction of the tissue factor gene in monocytes and endothelial cells. Lessons from the antiphospholipid syndrome. Thromb Haemost 109:525–531
22. Benhamou Y, Bellien J, Armengol G, Brakenchielm E, Adriouch S, Iacob M et al (2014) Role of toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome. Arthritis Rheumatol. doi:10.1002/art.38785
23. Bećarević M, Ignjatović S, Majkić-Singh N (2012) Deterioration of thromboses in primary antiphospholipid syndrome: TNFalpha and anti-annexin A5 antibodies. Clin Lab 58:1079–1084
24. Xie H, Zhou H, Wang H, Chen D, Xia L, Wang T et al (2013) Anti-βGPI/β2GPI induced TF and TNF-α expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling pathways. Mol Immunol 53:246–254
25. Lopez-Pedrera Ch, Buendia P, Aguirre MA, Velasco F, Cuadraro MJ (2006) Anthiphospholipid syndrome and tissue factor: a thrombotic couple. Lupus 15:161–166
26. Swadzba J, Iwaniec T, Musial J (2011) Increased level of tumor necrosis factor-α in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state. Rheumatol Int 31:307–313
27. Bertolaccini ML, Atsumi T, Lanchbury JS, Caliz AR, Katsumata K, Vaughan RW, Kondeatis E, Khamashta MA, Koike T, Hughes GRV (2001) Plasma tumor necrosis factor alpha levels and the-238*A promoter polymorphism in patients with antiphospholipid syndrome. Thromb Haemost 85:198–203
28. Bećarević M, Ignjatović S (2016) Proinflammatory proteins in female and male patients with primary antiphospholipid syndrome: preliminary data. Clin Rheumatol. doi:10.1007/s10067-016-3345-3
29. Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O et al (2002) Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106:2184–2187
30. Salmon JE, Alpert D (2006) Are we coming to terms with tumor necrosis factor inhibition in pregnancy? Arthritis Rheum 54:2353–2255
31. Berthelot JM, De Bandt M, Goupille P et al (2009) Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76:28–34
32. Winger EE, Reed JL, Ashoush S et al (2009) Treatment with adalimumab [HumiraR] and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol 61:113–120
33. Alijotas-Reig J (2013) Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus 22:6–17
34. Ballanti E, Perricone C, di Muzio G, Kroegler B, Chimenti MS, Graceffa D, Perricone R (2011) Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors. Autoimmun Rev 10:617–623
35. Familian A, Voskuyl AE, van Mierlo GJ, Heijst HA, Twisk JW, Dijkmans BA et al (2005) Infliximab treatment reduces complement activation in patients with rheumatoid arthritis. Ann Rheum Dis 64:1003–1008
36. Caramaschi P, Bambara LM, Pieropan S, Tinazzi I, Volpe A, Biasi D (2009) Anti-TNF alpha blockers, autoantibodies and autoimmune diseases. Joint Bone Spine 76:333–342
37. Aringer M, Steiner G, Graninger WB, Höfler E, Steiner CW, Smolen JS et al (2007) Effect of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 56:274–279
38. Ferraccioli G, Mecchia F, Di Poi E, Fabris M (2002) Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 61:358–361
39. Atzeni F, Sarzi-Puttini P, DellˈAcqua D et al (2006) Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 8:R3. doi:10.1186/ar1851
40. Eriksson C, Engstrand S, Sundqvist K-G, Rantapaa-Dahlqvist S (2005) Autoantibody formation in patients with theumatoid arthritis treated with anti-TNF-alpha. Ann Rheum Dis 64:403–407
41. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C (2004) Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 6:264–272
42. De Rycke L, Baeten D, Kruithof E, van den Bosch F, Veys EM, De Keyser F (2005) Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity. Arthritis Rheum 52:2192–2201
43. Nosbaum A, Goujon C, Fleury B et al (2007) Arterial thrombosis with anti-phospholipid antibodies induced by infliximab. Eur J Dermatol 17:546–547
44. Hemmati I, Kur J (2013) Adalimumab-associated antiphospholipid syndrome: a case report and review of the literature. Clin Rheumatol 32:1095–1098
45. Ramos-Casals M (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22(5):847–861. doi:10.1016/j.berh.2008.09.008
46. Makol A, Grover M, Guggenheim C, Hassouna H (2010) Etanercept and venous thromboembolism: a case series. J Med Case Rep 4:12
47. Bećarević M (2016) TNF-alpha and annexin A2: inflammation in thrombotic primary antiphospholipid syndrome. Rheumtol Int 36(12):1649–1656. doi:10.1007/s00296-016-3569-1
48. Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL (2011) Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70(10):1831–1834